Literature DB >> 16897099

[Systemic sclerosis--a challenge in rheumatology].

P Saar1, U Müller-Ladner.   

Abstract

The connective tissue disease systemic sclerosis (SSc) is still a challenge to every rheumatologist. SSc is characterized by progressing fibrosis of the skin and internal organs, abnormal activation of the immune system and distinct changes in microcirculation. Although it is a rare disease with a prevalence of about 20:100,000 one may come across it in daily practice. SSc is classified into limited and diffuse forms. Both entities usually involve internal organs. Life expectancy is limited and depends predominantly on the extent of the organs involved. Therefore, it is essential to diagnose SSc early and to identify and closely monitor the organs involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897099     DOI: 10.1007/s00393-006-0076-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  6 in total

1.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 3.  Immunological basis of systemic sclerosis.

Authors:  J-P Zuber; F Spertini
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

Review 4.  The role of DMARDs in systemic sclerosis therapy.

Authors:  N Blank; R Max; H-M Lorenz
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

Review 5.  D-penicillamine is not an effective treatment in systemic sclerosis.

Authors:  D E Furst; P J Clements
Journal:  Scand J Rheumatol       Date:  2001       Impact factor: 3.641

6.  Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.

Authors:  R Sgonc; M S Gruschwitz; G Boeck; N Sepp; J Gruber; G Wick
Journal:  Arthritis Rheum       Date:  2000-11
  6 in total
  2 in total

Review 1.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

2.  [Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)].

Authors:  N Hunzelmann; E Genth; T Krieg; M Meurer; I Melchers; P Moinzadeh; C Pfeiffer; G Riemekasten; E Schulze-Lohoff; C Sunderkoetter; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.